Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis

Ramzi Abboud, Fei Wan, Jacopo Mariotti, Marcos Arango, Luca Castagna, Rizwan Romee, Mehdi Hamadani, Saurabh Chhabra

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Haploidentical related donor transplantation (haplo-HCT) is associated with cytokine release syndrome (CRS). We conducted a multicenter retrospective study to analyze risk factors for CRS and outcomes after haplo-HCT. We included 451 patients from four academic centers receiving both peripheral blood and bone marrow grafts. Severe CRS was more common with PB vs. BM grafts (19.5% vs 4.9%, OR 2.9, p = 0.05). Multivariable analysis identified recipient CMV sero-positivity, prior transplant, HCT-CI score and donor–recipient sex mismatch as risk factors for severe CRS. Outcomes were analyzed with no CRS as the comparison group. Overall survival (OS) was superior with mild CRS (HR 0.64, p = 0.05) and worst with severe CRS (HR 2.12, p = 0.0038). Relapse risk was significantly decreased in both mild CRS (HR 0.38, p < 0.0001) and severe CRS (HR 0.17, p < 0.0001) groups. The risk of non-relapse mortality was notably higher in severe CRS group (HR 8.0, p < 0.0001), but not in mild CRS group. Acute GVHD was similar among groups. Chronic GVHD at 1 year was 18.5% for no CRS, 23% for mild CRS, and 4.3% for severe CRS (p = 0.0023), with the competing risk of early mortality and short follow up of surviving patients contributing to the low chronic GVHD rates in the severe CRS group.

Original languageEnglish
Pages (from-to)2763-2770
Number of pages8
JournalBone Marrow Transplantation
Volume56
Issue number11
DOIs
StatePublished - Nov 2021

Fingerprint

Dive into the research topics of 'Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis'. Together they form a unique fingerprint.

Cite this